Genotypic and Phenotypic Characterization of HIV-1 CRF01_AE env Molecular Clones From Infections in China

Robbins, 1995, Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum., J Infect Dis, 171, 1387, 10.1093/infdis/171.6.1387

Bradney, 1999, Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors., J Infect Dis, 179, 1264, 10.1086/314711

Zhang, 1997, Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors., J Infect Dis, 176, 1180, 10.1086/514111

Mascola, 2005, Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines., J Virol, 79, 10103, 10.1128/JVI.79.16.10103-10107.2005

Fenyo, 2009, International network for comparison of HIV neutralization assays: the NeutNet report., PLoS ONE, 4, e4505, 10.1371/journal.pone.0004505

Lu, 2008, The changing face of HIV in China., Nature, 455, 609, 10.1038/455609a

Lau, 2007, Emerging trends of HIV epidemiology in Asia., AIDS Rev, 9, 218

Chong, 2008, Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China., J Acquir Immune Defic Syndr, 47, 535, 10.1097/QAI.0b013e3181663967

Biswas, 2007, Access denied? The status of co-receptor inhibition to counter HIV entry., Expert Opin Pharmacother, 8, 923, 10.1517/14656566.8.7.923

Stephenson, 2007, Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus., JAMA, 297, 1535

Emmelkamp, 2007, CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature., Eur J Med Res, 12, 409

Wei, 2002, Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy., Antimicrob Agents Chemother, 46, 1896, 10.1128/AAC.46.6.1896-1905.2002

Platt, 1998, Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1., J Virol, 72, 2855, 10.1128/JVI.72.4.2855-2864.1998

Wei, 2003, Antibody neutralization and escape by HIV-1., Nature, 422, 307, 10.1038/nature01470

Fiebig, 2003, Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection., AIDS, 17, 1871, 10.1097/00002030-200309050-00005

Utachee, 2009, Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gAE env gene derived from HIV-1-infected patient, residing in central Thailand., Microbes Infect, 11, 334, 10.1016/j.micinf.2008.12.008

Li, 2005, Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies., J Virol, 79, 10108, 10.1128/JVI.79.16.10108-10125.2005

Li, 2006, Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa., J Virol, 80, 11776, 10.1128/JVI.01730-06

Utachee, 2009, Genotypic characterization of CRF01_AE env AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand., AIDS Res Hum Retroviruses, 25, 229, 10.1089/aid.2008.0232

Briz, 2006, HIV entry inhibitors: mechanisms of action and resistance pathways., J Antimicrob Chemother, 57, 619, 10.1093/jac/dkl027

Chohan, 2005, Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels., J Virol, 79, 6528, 10.1128/JVI.79.10.6528-6531.2005

Burton, 1994, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody., Science, 266, 1024, 10.1126/science.7973652

Mo, 1997, Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off., J Virol, 71, 6869, 10.1128/JVI.71.9.6869-6874.1997

Gray, 2006, Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B., PLoS Med, 3, e255, 10.1371/journal.pmed.0030255

Sanders, 2002, The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120., J Virol, 76, 7293, 10.1128/JVI.76.14.7293-7305.2002

Muster, 1993, A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1., J Virol, 67, 6642, 10.1128/JVI.67.11.6642-6647.1993

Zwick, 2005, Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1., J Virol, 79, 1252, 10.1128/JVI.79.2.1252-1261.2005

Lorizate, 2006, Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex., J Mol Biol, 360, 45, 10.1016/j.jmb.2006.04.056

Neurath, 1995, Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions., AIDS Res Hum Retroviruses, 11, 687, 10.1089/aid.1995.11.687

Zwick, 2001, Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41., J Virol, 75, 10892, 10.1128/JVI.75.22.10892-10905.2001

Brunel, 2006, Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody., J Virol, 80, 1680, 10.1128/JVI.80.4.1680-1687.2006

Blish, 2007, HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry., AIDS, 21, 693, 10.1097/QAD.0b013e32805e8727